At ASCO 2026, Dr Paul Richardson talks to ecancer about results from the phase III SUCCESSOR-2 study evaluating mezigdomide plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma previously exposed to anti-CD38 antibodies and lenalidomide. The combination significantly improved progression-free survival and response rates compared with carfilzomib and dexamethasone alone, in a population with limited treatment options.

Dr Richardson notes that these findings support mezigdomide as a potential new standard of care for relapsed or refractory multiple myeloma across multiple treatment settings.